+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Mutagenicity tests of tazobactam/piperacillin, tazobactam and piperacillin



Mutagenicity tests of tazobactam/piperacillin, tazobactam and piperacillin



Journal of Toxicological Sciences 19(Suppl. 2): 263-280



As a part of safety tests of tazobactam/piperacillin (TAZ/PIPC), the reverse mutation tests using bacteria, the chromosomal aberration tests using cultured cells and the micronucleus tests using male mice were conducted in order to evaluate the in vitro and in vivo mutagenicity of TAZ, PIPC, TAZ/PIPC. 1. The reverse mutation tests were carried out on TAZ, PIPC and TAZ/PIPC at dose ranges, where few antibacterial effects could be detected, using Salmonella typhimurium strains TA100, TA1535, TA98 and TA1537, and Escherichia coli Wp2uvrA. AU of three test articles showed that no significant increases were observed in the number of colonies in all tester strains in both systems, with and without mammalian metabolic activation (S9 Mix), as compared with solvent controls. 2. The chromosomal aberration tests were carried out on these test articles using cultured Chinese hamster lung cells (CHL). The cells were treated with TAZ, PIPC or TAZ/PIPC at the doses of 2.5, 5.0 and 10 mM with and without S9 Mix. In the test of PIPC with S9 Mix, the dose of 1.25 mM was set in addition to the three doses. The incidences of structural- and numeral- aberration were 0-3% in the absence or presence of mammalian metabolic activation system, and no significant increases were observed in the incidence of chromosomal aberrations as compared with solvent controls. 3. The micronucleus tests were carried out at doses of 625 apprx 5000 mg/kg of TAZ or TAZ/PIPC, or at 625-2500 mg/kg of PIPC. The femoral marrow cells were sampled 48 h after administering intravenously to CD-1 male mice. The frequencies of polychromatic erythrocyte with micronuclei were 0.02 apprx 0.17%, 0.02 apprx 0.10% and 0.03 apprx 0.07% in the groups treated with TAZ, PIPC and TAZ/PIPC, respectively, and no significant increases were observed with dose dependence. The results indicated that these test articles were negative in the assessment standard using the background data. 4. The present study indicates that TAZ, PIPC and TAZ/PIPC have no in vitro and in vivo mutagenic potential.

Please choose payment method:






(PDF emailed within 0-6 h: $19.90)

Accession: 009066297

Download citation: RISBibTeXText

PMID: 7830291

DOI: 10.2131/jts.19.supplementii_263


Related references

Multiple dose pharmacokinetics of piperacillin and tazobactam metabolites following piperacillin-tazobactam administration in healthy and renally impaired subjects. Pharmaceutical Research (New York) 9(10 Suppl. ): S326, 1992

Multicenter randomized clinical trial of piperacillin plus tazobactam vs piperacillin plus tazobactam and amikacin in the treatment of severe generalized peritonitis. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 38: 602, 1998

In Vitro-In Vivo Discordance with Humanized Piperacillin-Tazobactam Exposures against Piperacillin-Tazobactam-Resistant/Pan-β-Lactam-Susceptible Escherichia coli. Antimicrobial Agents and ChemoTherapy 60(12): 7527-7529, 2016

Piperacillin and tazobactam versus clindamycin and gentamicin in the treatment of hospitalized women with pelvic infection. The Piperacillin/tazobactam Study Group. Obstetrics and Gynecology 83(2): 280-286, 1994

Synergistic effect of polyethylenimine plus piperacillin/tazobactam on clinical Pseudomonas aeruginosa isolates resistant to piperacillin/tazobactam. Annals of Microbiology 56(4): 345-348, 2006

Piperacillin/tazobactam monotherapy versus piperacillin/tazobactam plus amikacin as initial empirical therapy for febrile neutropenia in children with acute leukemia. Pediatric Hematology and Oncology 28(4): 311-320, 2011

A national multicenter study of the in-vitro activity of piperacillin-tazobactam. The Spanish Piperacillin-Tazobactam Group. Revista Espanola de Quimioterapia 11(2): 139-146, 1998

Piperacillin/tazobactam-heteroresistant Pseudomonas aeruginosa from urinary infection, successfully treated by piperacillin/tazobactam. Journal of Antimicrobial ChemoTherapy 61(3): 757-758, 2008

Microbiological equivalence of bacteriostatic and bactericidal activities of the sera from healthy volunteers receiving generic piperacillin/tazobactam (Pipertaz) and original piperacillin/tazobactam (Tazocin). Journal of the Medical Association of Thailand 94(Suppl. 1): S196-S202, 2011

Piperacillin/tazobactam vs piperacillin/tazobactam plus amikacin as empiric therapy for fever in neutropenic patients. Blood 90(10 Suppl. 1 Part 2): 229B, 1997

Double-blind, randomized, clinical trial comparing monotherapy with piperacillin-tazobactam vs piperacillin-tazobactam plus amikacin as empiric therapy for febrile neutropenic cancer patients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 39: 722, 1999

A prospective randomized trial comparing the efficacy and safety of piperacillin/tazobactam versus piperacillin/tazobactam plus netilmicin in the treatment of febrile neutropenia in allogeneic stem cell recipients. Abstracts of the Interscience Conference on Antimicrobial Agents & Chemotherapy 41: 267, 2001

Antigenicity tests of tazobactam/piperacillin, tazobactam and piperacillin. Journal of Toxicological Sciences 19(Suppl. 2): 249-262, 1994

Comparative in vitro activity of piperacillin, piperacillin-sulbactam and piperacillin-tazobactam against nosocomial pathogens isolated from intensive care patients. Clinical Microbiology and Infection 9(11): 1128-1132, 2003

Serum bactericidal activity of piperacillin/tazobactam against Staphylococcus aureus, piperacillin-susceptible and piperacillin-resistant Escherichia coli and Pseudomonas aeruginosa. ChemoTherapy 50(1): 27-30, 2004